Citicoline.co helps a reader decide with a doctor, and it says when a study was negative, small, or industry-funded.
The job is an informed decision about citicoline (CDP-choline) without hype. Dr. Alexander Tabibi, MD, trained at USC Keck in internal medicine, is the author of record. Claims are graded. A negative trial is reported as a negative trial.
This is not a store and not a brand site. There is no own-label product. It is not a treatment guide. Citicoline is never presented as a treatment for stroke, dementia, glaucoma, ADHD, or brain injury. It is not a stacking forum.
Most citicoline (CDP-choline) content on the internet comes from companies that sell it. When the seller writes the summary, small trials become "promising breakthroughs," industry funding disappears, and negative results get buried under mechanism talk. The reader ends up with a sales pitch wearing a lab coat.
Citicoline.co was built to do the opposite. Every claim on this site is tied to a specific study and graded by strength. A large, well-run trial with a negative result carries more weight here than a small positive one funded by a supplement brand. That is not a marketing position. It is how evidence actually works.
The author of record is Dr. Alexander Tabibi, MD, who trained in internal medicine at USC Keck. Physician authorship matters for one reason: the job of this site is to read trials the way a clinician reads them, skeptically and in context. It is not to win an argument for or against a supplement.
Not all evidence is equal, and this site does not pretend it is. Claims fall into tiers.
The strongest tier is a large, randomized, placebo-controlled trial or a systematic review of such trials. Below that sit smaller randomized trials, which can be suggestive but are easy to over-read. Lower still are observational studies, which show associations but cannot prove cause. At the bottom is mechanism evidence, meaning laboratory and preclinical work showing how a compound behaves in cells or animals.
Mechanism evidence is where most supplement marketing lives. A plausible mechanism is a reason to run a trial, not a result. When this site describes citicoline's proposed support of membrane phospholipid synthesis, it says so plainly: neuroprotection is a preclinical finding. It is not something that has been shown to protect a human brain from stroke or dementia.
Here is the picture as it stands, with negative results given the same space as positive ones.
For acute stroke, earlier meta-analyses suggested benefit. Then the largest trial, ICTUS, published in The Lancet in 2012 with about 2,300 participants, found no improvement in 90-day recovery compared with placebo. A smaller signal that does not survive the biggest, best test is a signal the reader should discount. This site reports it that way.
For traumatic brain injury, the COBRIT trial, published in JAMA in 2012, found citicoline did not improve functional or cognitive outcomes versus placebo. That is a major, rigorous negative result, and it appears on this site without softening.
For chronic cerebrovascular cognitive decline, a Cochrane review found modest short-term benefit on memory and behaviour. But the trials were short and low quality, which limits what the finding can support. For mild vascular cognitive impairment, the observational IDEALE study found an association with stable scores versus decline in an untreated group, useful, but observational, and not proof.
For glaucoma, small trials reported changes in electrophysiological measures. Whether that translates into slowing actual vision loss is not established. For healthy adults, small industry-funded trials reported better attention-test scores at 250 and 500 mg, and a small industry-funded trial in adolescent males reported gains in attention and psychomotor speed. The funding source is disclosed every time these are cited.
For ADHD, there are no adequate trials. There is no good evidence citicoline treats ADHD, and this site says so on a dedicated page.
Sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately. No supplement is part of that response.
A short list of refusals defines the site as much as its content does.
It does not call citicoline a treatment. Not for stroke, dementia, glaucoma, ADHD, or brain injury, regardless of what any single small trial hinted at.
It does not sell a product. There is no own-label citicoline, no affiliate relationship, and no "best brands ranked" list designed to steer a purchase. The supplement selection page explains what to look for on a label, and the Cognizin page explains that Cognizin is a branded form of the same compound as citicoline, not a different molecule. Neither page exists to push a purchase.
It does not prescribe. The site never tells the reader what dose to take. It reports the doses used in trials, 250 to 2,000 mg per day, on the dosage page, because that is the honest framing. What a person should take, if anything, is a conversation with their own doctor.
It does not hide the funding problem. When a trial was funded by the maker of the ingredient being tested, the reader sees that fact next to the result, not in a footnote.
Safety is a claim like any other, so it is graded like any other. In trials, citicoline was generally well tolerated at 250 to 2,000 mg per day. Reported effects were mild: gastrointestinal upset, headache, and insomnia. The side effects page covers this in detail.
Two gaps matter. Pregnancy and breastfeeding data are lacking, so this site makes no reassurance there. And because citicoline may enhance the effects of levodopa, anyone with Parkinson's disease should involve their neurologist before considering it. That is a drug-interaction consideration, not a scare line, and it is stated on the safety page.
In the United States, citicoline is sold as a dietary supplement. It is not an FDA-approved drug. That status is stated wherever it is relevant, because it shapes what claims a label can legally make, and what a reader should expect from one.
Start with what citicoline is if the compound itself is new to you. The CDP-choline page clears up the naming, since CDP-choline and citicoline are the same compound and the two labels cause real confusion.
Then go to the evidence section, which is organized condition by condition, memory, ADHD, glaucoma, so the reader can see the full picture for each use rather than a highlight reel. The comparisons section, including citicoline vs alpha-GPC, covers the questions people ask when weighing choline sources against each other.
Before any decision, the questions to ask your doctor page turns the site's content into a practical conversation. That conversation is the point. This reference exists to make it better informed, not to replace it, and not to end with a checkout button.
If something on the site seems wrong or out of date, the contact page is open. Corrections are welcome. A reference that cannot be corrected is not a reference.